Published in Clin Cancer Res on September 01, 2006
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat Rev Cancer (2010) 3.74
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol (2012) 1.00
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer (2014) 1.00
Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells (2011) 0.90
Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res (2012) 0.88
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci (2015) 0.87
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia (2012) 0.86
Battle of the eternal rivals: restoring functional p53 and inhibiting Polo-like kinase 1 as cancer therapy. Oncotarget (2013) 0.86
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Protein Cell (2012) 0.83
A series of beta-carboline derivatives inhibit the kinase activity of PLKs. PLoS One (2012) 0.79
Human ABCB1 (P-glycoprotein) and ABCG2 mediate resistance to BI 2536, a potent and selective inhibitor of Polo-like kinase 1. Biochem Pharmacol (2013) 0.78
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Biomed Res Int (2015) 0.77
A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule. Acta Pharmacol Sin (2012) 0.77
Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma. Clin Transl Med (2016) 0.76
The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation. Mol Cancer Ther (2009) 0.75
Novel compounds in the treatment of lung cancer: current and developing therapeutic agents. J Exp Pharmacol (2011) 0.75
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 7.57
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol (2004) 4.48
Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05
Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther (2007) 3.61
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res (2002) 2.55
Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol (2005) 2.53
The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther (2002) 2.39
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding. Clin Cancer Res (2011) 2.12
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol (2005) 1.99
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther (2005) 1.67
The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer. Mol Cancer Ther (2004) 1.65
Perineural invasion and associated pain in pancreatic cancer. Nat Rev Cancer (2011) 1.64
RuleMonkey: software for stochastic simulation of rule-based models. BMC Bioinformatics (2010) 1.49
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med (2009) 1.48
Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther (2006) 1.41
Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol (2006) 1.39
Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res (2012) 1.33
Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res (2009) 1.29
Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther (2004) 1.24
Targeting Aurora-2 kinase in cancer. Mol Cancer Ther (2003) 1.23
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Mol Cancer Ther (2010) 1.20
Simulation of large-scale rule-based models. Bioinformatics (2009) 1.18
Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1.17
Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells. Clin Cancer Res (2011) 1.17
Identification of somatic mutations in cancer through Bayesian-based analysis of sequenced genome pairs. BMC Genomics (2013) 1.13
Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol (2006) 1.12
Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther (2008) 1.10
A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer. Breast Cancer Res Treat (2014) 1.08
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07
Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells. Cancer Res (2006) 1.06
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol (2008) 1.05
CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy. Mol Cancer Ther (2012) 1.05
Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. Yale J Biol Med (2009) 1.03
Down-regulation of Yes Associated Protein 1 expression reduces cell proliferation and clonogenicity of pancreatic cancer cells. PLoS One (2012) 1.02
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol (2006) 1.02
Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog (2013) 1.01
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors. Clin Cancer Res (2012) 1.01
UA62784, a novel inhibitor of centromere protein E kinesin-like protein. Mol Cancer Ther (2009) 1.01
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs (2010) 1.00
A historical perspective of anthracycline cardiotoxicity. Heart Fail Clin (2011) 0.99
Identification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1alpha-induced gene in pancreatic cancer. Pancreas (2008) 0.99
Quiescin sulfhydryl oxidase 1 promotes invasion of pancreatic tumor cells mediated by matrix metalloproteinases. Mol Cancer Res (2011) 0.98
A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. PLoS One (2013) 0.98
Small interfering RNA-mediated knockdown of PRL phosphatases results in altered Akt phosphorylation and reduced clonogenicity of pancreatic cancer cells. Mol Cancer Ther (2008) 0.97
Adrenocortical carcinoma survival rates correlated to genomic copy number variants. Mol Cancer Ther (2008) 0.96
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemother Pharmacol (2010) 0.96
Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. PLoS One (2012) 0.95
The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials. J Cancer (2012) 0.94
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs (2009) 0.93
Molecular characterization of interdigitating dendritic cell sarcoma. Rare Tumors (2010) 0.92
Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol (2011) 0.91
Functional genomics reveals diverse cellular processes that modulate tumor cell response to oxaliplatin. Mol Cancer Res (2010) 0.91
Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer (2011) 0.91
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol Cancer Ther (2006) 0.91
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells. Mol Cancer Res (2011) 0.91
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clin Cancer Res (2013) 0.90
Tubulin-associated proteins: Aurora and Polo-like kinases as therapeutic targets in cancer. Curr Oncol Rep (2008) 0.90
A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms. Clin Cancer Res (2004) 0.90
SnapShot: pancreatic cancer. Cancer Cell (2013) 0.90
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I. Cancer Res (2004) 0.89
DNA minor groove binders: back in the groove. Cancer Treat Rev (2009) 0.89
Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res (2004) 0.89
Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Syst Biol (2012) 0.88
Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors. Biochem Pharmacol (2011) 0.87
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies. Clin Cancer Res (2002) 0.87
Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urol Oncol (2009) 0.87
Topoisomerase I-DNA complex stability induced by camptothecins and its role in drug activity. Curr Med Chem Anticancer Agents (2004) 0.86
Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol (2006) 0.86
Basal cell nevus syndrome: a brave new world. Arch Dermatol (2010) 0.85
Evaluation of splicing efficiency in lymphoblastoid cell lines from patients with splicing-factor retinitis pigmentosa. Mol Vis (2008) 0.85
Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol Cancer Ther (2007) 0.84
Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol Cancer Ther (2003) 0.84
Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol Cancer Ther (2006) 0.84
Molecular Characterization of a Patient's Small Cell Carcinoma of the Ovary of the Hypercalcemic Type. J Cancer (2012) 0.84
Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer. N Engl J Med (2014) 0.83
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol (2014) 0.83
Patient selection for phase II trials. Am J Clin Oncol (2009) 0.83
Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic cancer. Cancer Res (2009) 0.83
Taxanes: impact on pancreatic cancer. Anticancer Drugs (2014) 0.83
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. Invest New Drugs (2011) 0.82
Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. Cancer (2011) 0.82
Determinants of patient screen failures in Phase 1 clinical trials. Invest New Drugs (2012) 0.82
Clonal evolution and therapeutic resistance in solid tumors. Front Pharmacol (2013) 0.81
Orchestrating the Tumor Microenvironment to Improve Survival for Patients With Pancreatic Cancer: Normalization, Not Destruction. Cancer J (2015) 0.81
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. Am J Clin Oncol (2013) 0.80
Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642). Invest New Drugs (2002) 0.80
Pdx-1-driven overexpression of aurora a kinase induces mild ductal dysplasia of pancreatic ducts near islets in transgenic mice. Pancreas (2008) 0.80
Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis. J Proteome Res (2013) 0.80
Transient hypoglycemic hemiparesis. J Natl Med Assoc (2002) 0.80
Three-dimensional printing of mitral valve using echocardiographic data. JACC Cardiovasc Imaging (2014) 0.80
Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats. Pharmacology (2007) 0.79
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas (2016) 0.78
Isolation and characterization of muscle fatigue substance with anti-tumor activities. J Cancer (2013) 0.78
Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. Ann Surg (2012) 0.78
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res (2006) 0.77
CBP501-calmodulin binding contributes to sensitizing tumor cells to cisplatin and bleomycin. Mol Cancer Ther (2011) 0.77